

1 **The Epidemiology of Hundreds of Individuals Infected with Omicron BA.1 in Middle-**  
2 **Eastern Jordan**

3 **Authors: Rima Hajjo<sup>1,2,3\*</sup>, Mahmoud M. AbuAlSamen<sup>1</sup>, Hamed M. Alzoubi<sup>1,4</sup>, Raeda**  
4 **Alqutob<sup>1</sup>**

5 **Affiliations:**

6 <sup>1</sup>Jordan CDC, Amman, Jordan (R.H., M.A.S, H.M.Z., R.Q.)

7 <sup>2</sup>Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman,  
8 Jordan (R.H.)

9 <sup>3</sup>Department of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The  
10 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (R.H.)

11 <sup>4</sup>Department of Microbiology and Immunology, Faculty of Medicine, Mutah University,  
12 Alkarak, Jordan (H.M.Z)

13 **\*Correspondence**

14 Rima Hajjo. E-mail: [rhajjo@gmail.com](mailto:rhajjo@gmail.com); [r.hajjo@zuj.edu.jo](mailto:r.hajjo@zuj.edu.jo)

15 **Keywords:** COVID-19, B.1.1.529, BA.1, omicron, SARS-CoV-2, variant of concern (VOC),  
16 Jordan CDC.

17 **Abstract**

18 In less than two months of its detection in Jordan, lineage B.1.1.529 recognized as omicron, is  
19 constituting 55% of all confirmed COVID-19 infections causing a rise in the daily cases in the

20 country. Herein, we report on 500 cases, among the first identified omicron infections in Jordan.  
21 We also report on the genomic diversity of 25 omicron viruses identified in nasopharyngeal  
22 swabs from Jordan. Our results indicated that 96% of study participants were vaccinated who  
23 had asymptomatic, mild or moderate disease. One unvaccinated individual developed severe  
24 disease. The median age of omicron cases was 30 years, and most frequent disease symptoms  
25 were: fever, coughing, sore throat, runny nose, general fatigue and muscle/joint pain. Viral  
26 genomic analysis results revealed that the BA.1 is the dominant omicron sublineage in Jordan,  
27 with 45 to 58 total mutations. We identified a few amino acid modifications that could impact  
28 the accuracy of some polymerase chain reaction (PCR) tests. In summary, infections caused by  
29 BA.1 seem milder than earlier infections. However, it is unknown whether this change is due to  
30 alterations in the immunity landscape of the infected population or is the result of viral genetic  
31 mutations that reduced viral virulence. Hence, comparing similar studies from different countries  
32 is likely to give us a get a better understanding of this variant, its behavior and the impact on  
33 disease characteristics.

## 34 **1. Introduction**

35 A new variant of concern (VOC) for the severe acute respiratory syndrome coronavirus 2  
36 (SARS-CoV-2) has been recently identified in early November 2021. The variant has been  
37 designated as PANGO lineage B.1.1.529(1), and was given the Latin name omicron by the  
38 World Health Organization (WHO)(2). B.1.1.529 has further diverged into three sub-lineages:  
39 BA.1 (the standard lineage), BA.2 and BA.3. Tracking BA.1 across different geographies is of  
40 paramount importance to get a better understanding of this new variant, and assess its impact on  
41 disease epidemiology and clinical outcome. Currently, omicron-infections make up 55% of all  
42 confirmed COVID-19 cases in Jordan, causing a rise in the daily cases (Figure 1A).

43 In order to get a better understanding of omicron BA.1, we sought to perform epidemiological  
44 characterization of the first identified omicron infections to characterize these infections  
45 according to gender, age, vaccination status, prior SARS-CoV-2 infections, disease symptoms  
46 and symptom severity. We also analyzed all available omicron genomic sequences available  
47 from GISAID(3).

## 48 **2. Materials and Methods**

### 49 *2.1. Epidemiologic Data*

50 Jordan CDC has developed a questionnaire and shared it with collaborators at the Jordanian  
51 Ministry of Health to be used by contact tracing teams in order to collect the research data from  
52 omicron-infected individuals described here. Data collection by contact tracing teams was  
53 conducted using phone-based interviews with confirmed cases. As of January 4<sup>th</sup>, 2022, 958  
54 records were retrieved and manually curated (*i.e.*, checked for duplications and missing data). A  
55 total of 500 cases were finally approved data analysis purposes. Textual data on symptoms were  
56 extracted, classified and combined into three levels of severity (mild, moderate and severe)  
57 according to Appendix Table 3. All statistics and analysis of proportions were performed in  
58 Microsoft<sup>®</sup> Excel for Mac version 16.57.

59 A reinfection was defined as being reinfected after 90 days of a prior SARS-CoV-2 infection  
60 confirmed with a PCR test. This study was approved by Al-Zaytoonah University Ethics  
61 Committee (IRB number: 29/11/2021-2022) and was conducted in accordance with the  
62 Declaration of Helsinki.

### 63 *2.2. Sequencing Data*

64 Sequencing specimens were collected using original nasopharyngeal swabs. Ion Torrent(4)  
65 assembly and Illumina MiSeq(5) were used as genome assembly methods depending on the  
66 originating lab. All sequencing specimens were collected by our collaborators at various  
67 diagnostic labs mentioned in the acknowledgement. Additional sequencing details are available  
68 on GISAID and GitHub: ([https://github.com/rhajjo/JCDC\\_OmicronData](https://github.com/rhajjo/JCDC_OmicronData)).

### 69 *2.3. Clade and Lineage Assignment*

70 Nextclade in Bioconda version 1.9.0.0(6) has been used to identify mutations in comparison with  
71 SARS-CoV-2 reference sequence (WIV04/MN996528.1). Nexclade uses the identified mutations  
72 in order to assign the sequences to specific clades and to place them on a reference phylogenetic  
73 tree with a subset of all sequences available in GISAID(3).

### 74 *2.4. Viral Genomic and Amino Acid (AA) Mutations*

75 CoVsurver available from GISAID(3) was used to rapidly screen the omicron genomes to screen  
76 AA changes in structural models and highlight if aa changes are close to common drug, host  
77 receptor or antibody binding sites.

## 78 **3. Results and Discussion**

### 79 *3.1. Epidemiological Characterization of the First Complete Set of 500 SARS-CoV-2 Omicron* 80 *Variant Cases in Jordan*

81 We analyzed contact tracing data from 500 respondents, out of the first 952 confirmed omicron-  
82 cases in Jordan, between December 1<sup>st</sup> thru January 4<sup>th</sup>, 2022. Raw textual data were manually  
83 curated, combined and analyzed to assess omicron-caused infections. Our results, which are  
84 based on reported data by infected respondents, revealed that 79.8% of the cases were reported in

85 the capital Amman, while the rest of the cases were distributed among other largely-populated  
86 Jordanian cities including Balqa, Irbid and Zarqa. Results showed that 45.8% of all cases were  
87 males and 45.0% were females. The median age for the infected individuals was 30 years.  
88 Besides, 40.4% of the infections were in age group 25–40 years old (adults), 19.6% in age group  
89 18-23 years old (youth), 7.8% in age group 2-17 years old (children) and 5.8% of all cases were  
90 in the age group 60 years old and above.

91 Symptomatic infections varied in severity and constituted 51.4% of all omicron infections among  
92 study respondents, while asymptomatic infections made up 31.4% of the total. Disease  
93 symptoms were mostly mild in 88.3% of the symptomatic infections, followed by moderate  
94 (9.7%) and severe symptoms (1.9%). The most frequent mild symptoms were fever (47.8%),  
95 coughing (47.1%), sore throat, (45.1%), runny nose (33.1%), joint and muscle pain (28.8%),  
96 general fatigue (31.5%), headache (13.2%), nasal congestion (16.3%) and hoarseness (9.3%).  
97 Notably, loss of taste and smell was only reported in 1.2% of the study cases.

98 Interestingly, 66.6% of the infected study individuals were fully vaccinated, *i.e.*, had received  
99 their complete vaccine doses, and 14 days had already passed since their last dose. Disease  
100 symptoms were mainly mild in the fully-vaccinated group. However, individuals who were fully-  
101 vaccinated and received a booster shot within the last few months (*i.e.*, 19.1% of the fully-  
102 vaccinated group) had asymptomatic infections in 44.1% of the cases, and mild symptoms in  
103 45.5% of the cases, moderate symptoms in 3.9% of the cases, but none had severe disease.

104 Our results revealed that 8.6% of the study individuals were reinfected with the omicron variant  
105 after 90 days from a prior SARS-CoV-2 infection. Most prior infections occurred between  
106 October 2020 and March 2021. Interestingly, reinfections ranged in severity from asymptomatic

107 to severe, with the majority being either asymptomatic (41.9%) or mild (44.2%). Nevertheless,  
108 2.3% of the reinfections were moderate, and 2.3% were severe. Epidemiologic results are  
109 summarized in Figure 1B. All details on the demographics data are available in Appendix  
110 (Appendix Tables 1-5).

### 111 3.2. Genomic Characterization of the First 25 Omicron Variant Viruses from Jordan

112 We analyzed all 25 complete viral genomes from Jordan, corresponding to omicron viruses  
113 publicly available on the Global Initiative on Sharing All Influenza Data (GISAID)(7) database  
114 prior to January 15<sup>th</sup>, 2022. Viral genomics data were preprocessed according to the methods  
115 described by Rambaut *et al*(8), We retained 23 sequences, which had at least 95% coverage of  
116 the reference genome (WIV04/MN996528.1)(9) after trimming the 5'- and 3'-untranslated  
117 regions, and excluding sequences with > 5% ambiguous base calls (Ns). A maximum likelihood  
118 tree for 23 viruses was estimated, and viral lineages were defined by pangolin(1). DNA sequence  
119 variations (SNVs) on the nucleotide and amino acid levels were determined after performing  
120 pairwise alignments of the viral sequences with the reference genome WIV04(9) using  
121 CoVsurver enabled by GISAID (Appendix).

122 Omicron genomic sequences from Jordan were all assigned to sublineage BA.1 using  
123 Nextclade in Bioconda version 1.9.0.0(11). The analyzed sequences differed in the total number  
124 of mutations which ranged from 45 to 58, as shown in Appendix (Appendix Table 6). These  
125 mutations included amino acid (AA) deletions and AA substitutions that could impact the  
126 sensitivity of many polymerase chain reaction tests (PCR tests) (Figure 1C). In fact, 21 (91.3%)  
127 sequences had 5 primer changes and 2 (8.7%) sequences had 3 primer changes in three PCR tests  
128 (Table 1). These primer changes impacted the sensitivity of many PCR tests and obligated urgent

129 updates on omicron diagnostic tests. Detailed genomic analysis results are provided on GitHub  
130 ([https://github.com/rhajjo/JCDC\\_OmicronData](https://github.com/rhajjo/JCDC_OmicronData)).

## 131 **5. Conclusions**

132 The observed changes in COVID-19 disease characteristics and omicron's genomic sequences  
133 highlight the need for large-scale studies that track the effects of viral mutational changes on  
134 disease epidemiology. Moreover, the identified positive impact of vaccines on reducing the  
135 severity of symptoms caused by omicron infections could support the ongoing efforts to reduce  
136 vaccine hesitancy in Jordan and around the world(12).

## 137 **Acknowledgments**

138 We gratefully acknowledge the Jordanian Ministry of Health for providing the contact  
139 tracing data, in particular we extend our thanks to Dr. Ali Zaitawi, Head of Directorate on  
140 Communicable Diseases, and; Dr. Alaa Abu Hudaib, Director of Surveillance. We also  
141 acknowledge all the Authors from the Originating and submitting laboratories (Biolab  
142 Diagnostic Laboratories, Ministry of Health, Medlabs and Princess Haya Biotechnology Center)  
143 responsible for obtaining the specimens, performing the genetic sequencing experiments,  
144 reporting and saring the data via the GISAID Initiative (<http://www.gisaid.org>). RH  
145 acknowledges support from the Deanship of Scientific Research at Al-Zaytoonah University of  
146 Jordan (Grant number 2020-2019/17/03).

## 147 **Data Availability**

148 Data files and results of the genomic analyses are provided on GitHub  
149 ([https://github.com/rhajjo/JCDC\\_OmicronData](https://github.com/rhajjo/JCDC_OmicronData)). The authors will make these data publicly  
150 available and supply additional details and a readme file upon request.

## 151 **Supporting Information**

152 Appendix for supplementary information on materials and methods, in addition to Appendix  
153 tables 1-6.

154 Appendix Table 1. Demographic data on omicron-infected cases (n=500).

155 Appendix Table 2. Disease severity among Omicron-infected cases

156 Appendix Table 3. Frequency of disease symptoms in symptomatic omicron infections.

157 Appendix Table 4. Vaccination status among omicron-infected cases.

158 Appendix Table 5. Reinfection statistics among omicron-infected cases.

159 Appendix Table 6. List of mutations in 23 omicron viruses from Jordan.

## 160 **Notes**

161 The authors declare no competing financial interest.

## 162 **References**

- 163 1. Cov-Lineages [Internet]. [cited 2022 Jan 17]. Available from: <https://cov->  
164 [lineages.org/global\\_report\\_B.1.1.529.html](https://cov-lineages.org/global_report_B.1.1.529.html)
- 165 2. Tracking SARS-CoV-2 variants [Internet]. [cited 2022 Jan 13]. Available from:  
166 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants>
- 167 3. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to  
168 reality. *Eurosurveillance* [Internet]. 2017 Mar 30 [cited 2021 Jan 28];22(13):30494.



- 169 Available from: [https://www.eurosurveillance.org/content/10.2807/1560-](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494)  
170 [7917.ES.2017.22.13.30494](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494)
- 171 4. Mangul S, Caciula A, al Seesi S, Brinza D, Măndoiu I, Zelikovsky A. Transcriptome assembly  
172 and quantification from Ion Torrent RNA-Seq data. *BMC Genomics* [Internet]. 2014 Jul 14  
173 [cited 2022 Jan 16];15(5):1–11. Available from:  
174 <https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-S5-S7>
- 175 5. MiSeq System | Focused power for targeted gene and small genome sequencing  
176 [Internet]. [cited 2022 Jan 16]. Available from:  
177 <https://www.illumina.com/systems/sequencing-platforms/miseq.html>
- 178 6. Package Recipe “nextclade” — Bioconda documentation [Internet]. [cited 2022 Jan 16].  
179 Available from: <https://bioconda.github.io/recipes/nextclade/README.html>
- 180 7. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to  
181 reality [Internet]. Vol. 22, *Eurosurveillance*. European Centre for Disease Prevention and  
182 Control (ECDC); 2017 [cited 2021 Feb 1]. p. 1. Available from:  
183 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388101/>
- 184 8. Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic  
185 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature*  
186 *Microbiology* [Internet]. 2020 Nov 1 [cited 2021 Jan 28];5(11):1403–7. Available from:  
187 <https://doi.org/10.1038/s41564-020-0770-5>
- 188 9. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak  
189 associated with a new coronavirus of probable bat origin. *Nature* 2020 579:7798  
190 [Internet]. 2020 Feb 3 [cited 2022 Jan 15];579(7798):270–3. Available from:  
191 <https://www.nature.com/articles/s41586-020-2012-7>
- 192 10. PANGO lineages [Internet]. [cited 2021 Jan 28]. Available from: [https://cov-](https://cov-lineages.org/pangolin.html)  
193 [lineages.org/pangolin.html](https://cov-lineages.org/pangolin.html)
- 194 11. Dale R, Grüning B, Sjödin A, Rowe J, Chapman BA, Tomkins-Tinch CH, et al. Bioconda:  
195 Sustainable and comprehensive software distribution for the life sciences. *Nature*  
196 *Methods*. 2018 Jul 1;15(7):475–6.
- 197 12. Al-Qerem WA, Jarab AS. COVID-19 Vaccination Acceptance and Its Associated Factors  
198 Among a Middle Eastern Population. *Frontiers in Public Health*. 2021 Feb 10;9:34.

199  
200 Address for correspondence: Rima Hajjo, 1Department of Pharmacy, Faculty of Pharmacy,  
201 Al-Zaytoonah University of Jordan, P.O. Box 130 Amman 11733 Jordan.

202      [rhajjo@gmail.com](mailto:rhajjo@gmail.com); [r.hajjo@zuj.edu.jo](mailto:r.hajjo@zuj.edu.jo)

203      Dr. Hajjo is an Assistant Professor of Pharmacogenetics and Pharmacoinformatics at Al-  
204      Zaytoonah University of Jordan, an Adjunct Associate Professor at UNC-Chapel Hill, and a  
205      Board Member at the National Center for Epidemics and Communicable Disease Control in  
206      Amman, Jordan. <https://orcid.org/0000-0002-7090-5425>

207


208 **Table 1.** PCR primer changes in omicron viral sequences identified in Jordan.

Nucleotide Change*	Primer†	Number of Sequences‡
C26270T	Charité_E_F	23
C28311T	USCDC_N1_P	23
G28881A	ChinaCDC_N_F	22
G28882A	ChinaCDC_N_F	22
G28883C	ChinaCDC_N_F	22

209 \*Observed nucleotide change in omicron viral genomic sequences identified in Jordan by  
210 sequencing. †Impacted primers by the observed nucleotide change. ‡The number of viral  
211 genomic sequences from Jordan that contain the nucleotide changes listed in column 1.


212 **Figure 1.** Epidemiologic and viral genomic data from omicron cases in Jordan. A) Daily  
213 COVID-19 cases and deaths in Jordan over time as of January 16<sup>th</sup>, 2022. B) Summary statistics  
214 of epidemiologic data collected from 500 omicron-infected cases from Jordan. C) Summary  
215 statistics of important mutational changes in omicron viruses identified in Jordan and led to PCR  
216 primer changes and amino acid changes (deletions and substitutions).

A




B


### % Infections by Sex





### % Infections by Age Group




### % Infections by Vaccination Status




### Recent Travel History



### Disease Characteristics




### Most Frequent Symptoms




C

### Total PCR Primer Changes



### Total AA Deletions



### Total AA Substitutions

